How has been the historical performance of Ishita Drugs?

Answer:The historical performance of Ishita Drugs shows a mixed trend in financial metrics over the years leading up to March 2025.

Breakdown:
Ishita Drugs reported net sales of 15.00 Cr in March 2025, a slight decrease from 15.19 Cr in March 2024, but an increase from 12.07 Cr in March 2023. The total operating income mirrored the net sales, remaining at 15.00 Cr in March 2025. The total expenditure, excluding depreciation, was 14.00 Cr in March 2025, down from 14.28 Cr in March 2024, while the operating profit (PBDIT) increased to 1.34 Cr from 1.19 Cr in the previous year. Profit before tax rose to 1.16 Cr in March 2025, compared to 0.99 Cr in March 2024, and profit after tax also increased to 0.87 Cr from 0.75 Cr. The earnings per share (EPS) improved to 2.91 in March 2025, up from 2.51 in March 2024. On the balance sheet, total assets grew to 16.30 Cr in March 2025 from 10.81 Cr in March 2024, driven by an increase in current assets, particularly inventories and cash. Total liabilities also rose to 16.30 Cr, with short-term borrowings increasing significantly to 3.81 Cr in March 2025 from 0.00 Cr in March 2024. The cash flow from operating activities showed a negative trend, recording -3.00 Cr in March 2025, down from 2.00 Cr in March 2024, while cash flow from financing activities was positive at 4.00 Cr in March 2025. Overall, while Ishita Drugs has shown growth in sales and profits, it faces challenges in cash flow management and increasing liabilities.